GSK2837808A is primarily researched for its potential application in the treatment of cancer, particularly in targeting specific metabolic pathways in cancer cells. It functions as an inhibitor of lactate dehydrogenase A (LDHA), an enzyme that plays a critical role in the anaerobic glycolysis process, which is often upregulated in cancer cells to support their rapid growth and survival. By inhibiting LDHA, GSK2837808A disrupts the energy production of cancer cells, potentially leading to reduced tumor growth and increased susceptibility to other cancer therapies. Its application is being explored in preclinical and early clinical studies to evaluate its efficacy in various cancer types, especially those reliant on glycolysis for energy. Additionally, it may be used in combination with other treatments to enhance therapeutic outcomes.